Ecor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc purchased 65,184 shares of AnaptysBio stock. The shares were bought at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Trading Up 0.9 %

ANAB opened at $13.36 on Friday. The stock’s 50-day moving average price is $20.10 and its 200 day moving average price is $28.50. AnaptysBio, Inc. has a 12-month low of $12.51 and a 12-month high of $41.31. The firm has a market cap of $406.53 million, a price-to-earnings ratio of -2.20 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, research analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in shares of AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after acquiring an additional 438,557 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the period. Assenagon Asset Management S.A. raised its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of AnaptysBio by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after buying an additional 13,336 shares during the period. Finally, Jennison Associates LLC purchased a new position in shares of AnaptysBio in the 3rd quarter valued at about $8,874,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Truist Financial cut their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Guggenheim reduced their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.